Does the media refer more to ORIC or ATRA?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat Oric Pharmaceuticals' score of 0.47 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STTK or ATRA?

In the previous week, Shattuck Labs had 20 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 22 mentions for Shattuck Labs and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat Shattuck Labs' score of 0.44 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 4 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATRA or SOPH?

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat SOPHiA GENETICS's score of 0.45 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOPHiA GENETICS 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AVIR or ATRA?

Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential downside of 9.18%. Given Atara Biotherapeutics' higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Atara Biotherapeutics (ATRA) Competitors

$10.46 +0.60 (+6.09%)

As of 04:00 PM Eastern

Compare

ATRA vs. ORIC, STTK, LXEO, SOPH, and AVIR

Should you buy Atara Biotherapeutics stock or one of its competitors? MarketBeat compares Atara Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), Shattuck Labs (STTK), Lexeo Therapeutics (LXEO), SOPHiA GENETICS (SOPH), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Oric Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat Oric Pharmaceuticals' score of 0.47 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Atara Biotherapeutics	$120.77M	0.78	$32.69M	-$0.67	N/A

Oric Pharmaceuticals presently has a consensus price target of $19.36, suggesting a potential upside of 147.62%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential downside of 9.18%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Oric Pharmaceuticals' return on equity of -35.33% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Oric Pharmaceuticals beats Atara Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Shattuck Labs has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Shattuck Labs' return on equity of -60.73% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Shattuck Labs currently has a consensus target price of $11.00, suggesting a potential upside of 163.16%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential downside of 9.18%. Given Shattuck Labs' stronger consensus rating and higher probable upside, research analysts clearly believe Shattuck Labs is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

In the previous week, Shattuck Labs had 20 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 22 mentions for Shattuck Labs and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat Shattuck Labs' score of 0.44 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	4 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Shattuck Labs. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	320.52	-$48.81M	-$0.63	N/A
Atara Biotherapeutics	$120.77M	0.78	$32.69M	-$0.67	N/A

Summary

Shattuck Labs beats Atara Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Lexeo Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market.

Lexeo Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Lexeo Therapeutics' return on equity of -47.48% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Lexeo Therapeutics presently has a consensus price target of $20.14, suggesting a potential upside of 379.59%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential downside of 9.18%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 2 mentions for Atara Biotherapeutics and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.87 beat Atara Biotherapeutics' score of 0.93 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Very Positive
Atara Biotherapeutics	Positive

Atara Biotherapeutics has higher revenue and earnings than Lexeo Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Atara Biotherapeutics	$120.77M	0.78	$32.69M	-$0.67	N/A

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Lexeo Therapeutics beats Atara Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to SOPHiA GENETICS?

Atara Biotherapeutics (NASDAQ:ATRA) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.93 beat SOPHiA GENETICS's score of 0.45 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atara Biotherapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential downside of 9.18%. SOPHiA GENETICS has a consensus price target of $7.50, indicating a potential upside of 44.23%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Atara Biotherapeutics has higher revenue and earnings than SOPHiA GENETICS. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.78	$32.69M	-$0.67	N/A
SOPHiA GENETICS	$77.27M	4.61	-$79M	-$0.52	N/A

Atara Biotherapeutics has a net margin of -40.91% compared to SOPHiA GENETICS's net margin of -44.48%. SOPHiA GENETICS's return on equity of -62.74% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Summary

SOPHiA GENETICS beats Atara Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential downside of 9.18%. Given Atara Biotherapeutics' higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atara Biotherapeutics has higher revenue and earnings than Atea Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Atara Biotherapeutics	$120.77M	0.78	$32.69M	-$0.67	N/A

Atea Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market.

Atea Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atea Pharmaceuticals' return on equity of -57.01% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for Atara Biotherapeutics and 1 mentions for Atea Pharmaceuticals. Atara Biotherapeutics' average media sentiment score of 0.93 beat Atea Pharmaceuticals' score of 0.43 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Atara Biotherapeutics	Positive

Summary

Atara Biotherapeutics beats Atea Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRA vs. The Competition

Export

Metric	Atara Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$88.84M	$3.29B	$6.47B	$11.73B
Dividend Yield	N/A	2.33%	2.67%	5.56%
P/E Ratio	-15.61	10.85	20.64	22.08
Price / Sales	0.78	301.53	503.66	108.52
Price / Cash	2.03	120.36	43.20	54.62
Price / Book	-1.96	8.21	10.50	6.82
Net Income	$32.69M	$23.89M	$3.56B	$337.41M
7 Day Performance	1.45%	-3.00%	-2.02%	-0.96%
1 Month Performance	19.13%	-1.64%	0.66%	1.68%
1 Year Performance	17.40%	40.20%	21.85%	26.88%

Atara Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRA Atara Biotherapeutics	1.5009 of 5 stars	$10.46 +6.1%	$9.50 -9.2%	+8.1%	$88.84M	$120.77M	N/A	330
ORIC Oric Pharmaceuticals	2.5915 of 5 stars	$7.53 +0.4%	$19.36 +157.2%	-22.7%	$776.38M	N/A	N/A	80	Analyst Forecast
STTK Shattuck Labs	4.5334 of 5 stars	$3.90 -14.8%	$11.00 +182.1%	+256.0%	$351.20M	$1M	N/A	100	News Coverage Analyst Forecast Insider Trade High Trading Volume
LXEO Lexeo Therapeutics	2.2864 of 5 stars	$4.21 -3.7%	$20.14 +378.5%	-10.4%	$343.14M	N/A	N/A	58
SOPH SOPHiA GENETICS	2.2739 of 5 stars	$5.28 +5.6%	$7.50 +42.0%	+74.6%	$342.43M	$81.18M	N/A	520	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRA) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, STTK, LXEO, SOPH, and AVIR

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Shattuck Labs?

Summary

How does Atara Biotherapeutics compare to Lexeo Therapeutics?

Summary

How does Atara Biotherapeutics compare to SOPHiA GENETICS?

Summary

How does Atara Biotherapeutics compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, STTK, LXEO, SOPH, and AVIR

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Which has more volatility and risk, ORIC or ATRA?

Does the media refer more to ORIC or ATRA?

Which has higher valuation & earnings, ORIC or ATRA?

Do analysts rate ORIC or ATRA?

Is ORIC or ATRA more profitable?

Do insiders & institutionals have more ownership in ORIC or ATRA?

Summary

How does Atara Biotherapeutics compare to Shattuck Labs?

Is STTK or ATRA more profitable?

Do analysts prefer STTK or ATRA?

Which has more volatility and risk, STTK or ATRA?

Does the media prefer STTK or ATRA?

Do insiders and institutionals hold more shares of STTK or ATRA?

Which has stronger valuation & earnings, STTK or ATRA?

Summary

How does Atara Biotherapeutics compare to Lexeo Therapeutics?

Which has more volatility & risk, LXEO or ATRA?

Is LXEO or ATRA more profitable?

Do analysts recommend LXEO or ATRA?

Does the media prefer LXEO or ATRA?

Which has higher earnings and valuation, LXEO or ATRA?

Do institutionals & insiders hold more shares of LXEO or ATRA?

Summary

How does Atara Biotherapeutics compare to SOPHiA GENETICS?

Do institutionals and insiders have more ownership in ATRA or SOPH?

Does the media favor ATRA or SOPH?

Which has more volatility & risk, ATRA or SOPH?

Do analysts rate ATRA or SOPH?

Which has better earnings & valuation, ATRA or SOPH?

Is ATRA or SOPH more profitable?

Summary

How does Atara Biotherapeutics compare to Atea Pharmaceuticals?

Do institutionals & insiders believe in AVIR or ATRA?

Do analysts rate AVIR or ATRA?

Which has stronger earnings & valuation, AVIR or ATRA?

Which has more volatility and risk, AVIR or ATRA?

Is AVIR or ATRA more profitable?

Does the media prefer AVIR or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools